Pfizer’s colorectal cancer combo therapy gains accelerated approval from FDA
Pfizer has gained accelerated approval from the US FDA for BRAFTOVI in conjunction with cetuximab and mFOLFOX6 for treating mCRC.
Pfizer has gained accelerated approval from the US FDA for BRAFTOVI in conjunction with cetuximab and mFOLFOX6 for treating mCRC.
What's Your Reaction?
